Company Profile
Phio Pharmaceuticals Stock Price, News & Catalysts
- Ticker:
- PHIO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.99 USD (+0.34%)
Close
Last updated: October 6, 2026
13M USD
Market cap
Why the stock is moving
As of Oct 6, 2026, PHIO closed up 0.34% at $0.9944. No new same-company headline was identified in the current news window.
Company overview
Clinical-Stage RNA Interference Company
Phio Pharmaceuticals develops locally administered small interfering RNA medicines for cancer. Its strategy is to silence immune-suppressive genes directly within tumors and thereby strengthen the activity of immune cells in the tumor microenvironment.
INTASYL Gene-Silencing Platform
INTASYL compounds are self-delivering siRNA molecules designed to enter target cells without a separate delivery vehicle. The platform can be directed against immune checkpoints and other genes that limit antitumor immunity.
PH-762 Lead Program
PH-762 silences the PD-1 gene and is being developed as an intratumoral treatment for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Its completed Phase 1b study evaluated neoadjuvant use, safety, tumor response, and dose selection.
Focused Development and Manufacturing Strategy
Phio is concentrating resources on PH-762 while preparing commercial-scale active pharmaceutical ingredient production and longer-term toxicology work. These activities are intended to support the next clinical study and establish a more mature chemistry, manufacturing, and controls package.
Future catalysts
- FDA meeting in the third quarter of 2026 to discuss the next PH-762 clinical-study design and development strategy.
- Completion of commercial-scale API work and the long-term PH-762 nonclinical toxicology study by year-end 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Phio Pharmaceuticals (PHIO)?
Phio Pharmaceuticals (PHIO) most recently closed at 0.99 USD, a +0.34% move versus the previous session.
What is the market cap of Phio Pharmaceuticals (PHIO)?
Phio Pharmaceuticals currently has a market capitalization of 13M USD on BioPharmSignal.
What does Phio Pharmaceuticals do?
Clinical-Stage RNA Interference Company Phio Pharmaceuticals develops locally administered small interfering RNA medicines for cancer. Its strategy is to silence immune-suppressive genes directly within tumors and thereby strengthen the activity of immune cells in the tumor microenvironment. INTASYL Gene-Silencing Platform INTASYL compounds are...
On which exchange is PHIO stock listed?
Phio Pharmaceuticals (PHIO) is associated with NASDAQ, United States, Biopharma.
What is PH-762?
FDA meeting in the third quarter of 2026 to discuss the next PH-762 clinical-study design and development strategy.
Which conditions is Phio Pharmaceuticals targeting with PH-762?
Phio Pharmaceuticals is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Phio Pharmaceuticals describe recent progress with PH-762?
FDA meeting in the third quarter of 2026 to discuss the next PH-762 clinical-study design and development strategy.
What is PD-1?
PH-762 Lead Program PH-762 silences the PD-1 gene and is being developed as an intratumoral treatment for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.